Integrating Discovery, Improving Efficiency

RTX-003 is a targeted anti-CD25 monoclonal antibody that binds CD25 without blocking IL-2 on the high-affinity IL-2 receptor alpha on T regulatory (T reg) cells.   Increased T regulatory cells and/or decreased active T cells in a tumor correlate with lower Overall Survival (OS) and Progression-Free Survival (PFS) in a variety of tumor types.  RTX-003 is designed to induce T reg cell death, eliminating the suppressing influence Treg cells impose, thus supporting tumor immunity.